Protein-based nanoparticle vaccine for metapneumovirus
AssigneeIcosavax, Inc.
InventorsAndrew Lawrence Feldhaus, Douglas Andrew Holtzman, Clancey Buchanan Wolf
Life of this patent
Estimating the term…
Abstract
Provided are virus-like particle vaccines for human metapneumovirus (hMPV) in which the ectodomain of hMPV F protein is linked to, and thereby displayed on, a symmetric protein-based virus-like particle. For example, the vaccine antigen may be a N-terminal fusion of the ectodomain of hMPV F protein to a protein having a multimerization domain for a one- or two-component virus-like particle, such as a two-component icosahedral virus-like particle. Further provided are vaccine compositions, methods of manufacturing, and methods of use, e.g., immunizing a subject to generate a protective immune response to hMPV.
Claims35
A virus-like particle (VLP), comprising a first component and optionally a second component,
- wherein the first component is a fusion protein, comprising a human metapneumovirus (hMPV) F protein ectodomain or antigenic variant thereof, and a first multimerization domain;
- wherein the second component, if present, is a protein comprising a second multimerization domain;
- and
- wherein the first multimerization domain is selected from SEQ ID NOS:
- 1, 4, 5, 7, 9, 18, 19, 21, 24, 25, 26, 29, 30, 31, 34, 36, 37, 39, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 144, 145, or functional variants thereof.
Dependencies are inferred from the claim text.